Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Change in Cash (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Change in Cash for 17 consecutive years, with -$3.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Cash fell 266.67% to -$3.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $39.4 million, a 235.86% increase, with the full-year FY2025 number at $39.4 million, up 235.86% from a year prior.
  • Change in Cash was -$3.5 million for Q4 2025 at Myriad Genetics, down from $71.1 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $176.8 million in Q3 2021 to a low of -$93.2 million in Q1 2022.
  • A 5-year average of $1.7 million and a median of -$4.0 million in 2024 define the central range for Change in Cash.
  • Peak YoY movement for Change in Cash: plummeted 969.7% in 2024, then skyrocketed 726.74% in 2025.
  • Myriad Genetics' Change in Cash stood at -$36.4 million in 2021, then dropped by 21.7% to -$44.3 million in 2022, then soared by 226.19% to $55.9 million in 2023, then crashed by 96.24% to $2.1 million in 2024, then crashed by 266.67% to -$3.5 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Change in Cash are -$3.5 million (Q4 2025), $71.1 million (Q3 2025), and -$17.3 million (Q2 2025).